APSR IDI Online KlikPDPI Halaman Admin Forum Umum Facebook Page Twitter Instagram Youtube
Expression and Clinical Implications of the Estrogen Receptor β in Lung Adenocarcinoma
PDPI Lampung & Bengkulu, 29 Jun 2019 18:56:36
Abstract Estrogens behave as promoters in the process of carcinogenesis, via receptor-mediated mechanisms. ERβ expression is excessively higher in lung cancer than ERα expression. The objectives of this study were to establish the treatment response and survival differences between the sexes of lung adenocarcinoma patients depending on the presence of ERβ in the tumor tissue. The study included 200 patients with diagnosis of lung adenocarcinoma. The hormone receptor's expression in tumor tissue samples was determined by immunohistochemistry method using the primary monoclonal estrogen receptor (beta) antibody, Clone EMR02, NCL-ER-beta. The disease progression and the treatment response were more frequently registered in ERβ- patients. In the female patients, the disease progression was more frequently registered in ERβ- than in ERβ+ patients. Neither was a statistically significant difference registered in the time passing till the onset of the disease progression in the overall examined population, unlike in the examined females, in whom it was 16.5 and 9.5 months with ERβ+ and ERβ- tumor status respectively making statistically significant difference (p=0.041). The analysis of the cumulative survival depending on the patients' sex and receptor status (males ERβ-, males ERβ+, females ERβ-, females ERβ+) has revealed that ERβ+ females had a significantly longer survival than other three subgroups (Breslow: p=0.037; Mantel-Cox: p=0.112). The hormonal receptor status is doubtlessly one of many factors in lung cancer carcinogenesis and may be establish as a prognostic factor in lung cancer and potential factor in multi modal (hormonal therapy-anti estrogen) treatment of this malignancy.
Tutorial Aplikasi ISR
Uploaded on May 11, 2015
World Asthma Day 2018
Uploaded on Apr 30, 2018